ALLO Allogene Therapeutics, Inc.
Healthcare$2.00+2.04%ClosedMarket Cap: $487.7M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
1.72
P/S
0.00
EV/EBITDA
-3.20
DCF Value
$-0.12
FCF Yield
-22.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-56.4%
ROA
-43.9%
ROIC
-50.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-46.1M | $-42.6M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-42.4M | $-38.8M | $— | — |
| FY null | $0.00 | -Infinity% | $-206.9M | $-190.9M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-44.9M | $-41.4M | $— | — |
| Q2 null | $0.00 | NaN% | $-56.8M | $-50.9M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-65.2M | $-59.7M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-60.5M | $-59.9M | $— | — |
| FY null | $22.0K | 100.0% | $-273.2M | $-257.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-71.8M | $-66.3M | $— | — |
| Q2 null | $0.00 | NaN% | $-71.4M | $-66.4M | $— | — |
| Q1 null | $22.0K | -16059.1% | $-69.5M | $-65.0M | $— | — |
| Q4 2023 | $-44.0K | 100.0% | $-85.2M | $-89.3M | $-0.51 | — |